Latest News for: metastatic

Edit

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic ...

Nasdaq Globe Newswire 04 Nov 2021
... with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo, in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
Edit

Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer (Ambrx Biopharma Inc)

Public Technologies 04 Nov 2021
AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the first patient has been dosed in its global ACE-Breast-03 Phase 2 clinical study of ARX788 in patients with HER2-positive metastatic breast cancer.
Edit

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer (XOMA Corporation)

Public Technologies 04 Nov 2021
) XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer ... with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo, in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
Edit

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

PR Newswire 04 Nov 2021
... unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma ... Currently, the 5-year survival rate of advanced or metastatic gastric cancer ranges from 5 to 20 percent, and the median overall survival is approximately one year.
Edit

EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson (McKesson Corporation)

Public Technologies 03 Nov 2021
... treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (mNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Edit

Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027

The Salamanca Press 03 Nov 2021
The trial is being managed by AIO, a leading academic cooperative medical oncology group based in Germany, and is designed to investigate the use of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers.
Edit

Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer (Sorrento Therapeutics Inc)

Public Technologies 01 Nov 2021
Sorrento's License Partner, Lee's Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer ... Sorrento to COF for the greater China territory to treat recurrent or metastatic cervical cancer.
Edit

5 Things to Know About HER2-Positive Metastatic Breast Cancer

Douglas County News-Press 30 Oct 2021
(BPT) - The breast cancer treatment journey – something nearly one in eight women will experience sometime in their lifetime – can be overwhelming and filled with uncertainty. To hear ....
Edit

Living with HER2 Positive Metastatic Breast Cancer

Purcell Register 30 Oct 2021
“So, at that point, I didn’t do anything about it,” Terri said. “I thought it was nothing.” ... After a PET scan and biopsy, Terri was told she had HER2 positive metastatic breast cancer (MBC) ... “I want people to know that life does go on after a metastatic breast cancer diagnosis,” Terri said ... I know ... ....
Edit

One Woman's Optimistic Outlook After A HER2 Positive Metastatic Breast Cancer Diagnosis

Purcell Register 30 Oct 2021
also face, according to the American Cancer Society - Julie is living with metastatic breast cancer ... This time, Julie was diagnosed with HER2 positive metastatic breast cancer ... “Through my story, I want other women living with HER2 positive metastatic breast cancer to be ...
Edit

Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors - Discovered by, and Validation of, Kiromic’s Proprietary DIAMOND® Artificial Intelligence Platform - Form 8-K (Kiromic Biopharma Inc)

Public Technologies 29 Oct 2021
... one of the patients with metastatic pancreatic cancer who participated in the trial ... "We are very proud of the results we achieved with KiroVax/BSK01 in addressing advanced metastatic pancreatic cancer ... The new, metastatic tumor is the same type of cancer as the primary tumor.
Edit

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic ...

Nasdaq Globe Newswire 28 Oct 2021
... metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of overall survival.
Edit

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia (Rafael Holdings Inc)

Public Technologies 28 Oct 2021
In this multi-national Phase 3 randomized clinical trial, 528 patients with metastatic adenocarcinoma of the pancreas who had no prior therapy were randomized to receive either devimistat in combination with modified FOLFIRINOX (mFFX) or FOLFIRINOX, a current standard of care chemotherapy regimen.
×